Baudax Bio announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases. Gerri Henwood, President and Chief Executive Officer of Baudax Bio, will continue as CEO of the combined entity. In conjunction with the transaction, Yong Chan Kim, Ph D, former Chief Executive Officer of TeraImmune, will be appointed to the Board of Directors of Baudax.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BXRX:
- Baudax Bio Soars on Snapping Up Cell Therapy Developer TeraImmune
- Baudax Bio Acquires TeraImmune, Inc.
- Baudax Bio files to sell 785K shares of common stock for holders
- Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
- Baudax Bio Announces Date of Reconvened Annual Meeting
